Aristotle Atlantic Partners’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Aristotle Atlantic Partners's ADPT Position: Q3 2026 in Review
Aristotle Atlantic Partners increased its Adaptive Biotechnologies (ADPT) stake by 0.85% in Q3 2026, buying an estimated $385K and bringing the position to 1,854,200 shares worth $53.6M. The position accounts for 2.09% of the portfolio, ranked #16.
Aristotle Atlantic Partners first reported a position in ADPT in Q3 2019 and has held it in 29 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.
- Aristotle Atlantic Partners held 1,854,200 shares of Adaptive Biotechnologies worth $53.6M as of Q3 2026.
- Aristotle Atlantic Partners bought 15,687 Adaptive Biotechnologies shares in Q3 2026, an estimated $385K.
- Adaptive Biotechnologies made up 2.09% of Aristotle Atlantic Partners's portfolio in Q3 2026, its #16 holding.
- Aristotle Atlantic Partners first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 29 quarters since.
- 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.
Based on Aristotle Atlantic Partners's 13F filing for Q3 2026, filed 16 Nov 2026.